Product Facts

  • Individual dosing varies from 5000 to 10000 USP units hCG.
  • Can be stored at room temperature (15°C-30°C or 59°F-86°F) prior to reconstitution.
  • Reconstituted solution is stable for 60 days when refrigerated.

Indication

PREGNYL is indicated for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.

Selected Safety Information About PREGNYL® (chorionic gonadotropin for injection, USP)

PREGNYL is contraindicated in patients with prior allergic reaction to human chorionic gonadotropin (hCG).

PREGNYL should be used in conjunction with human menopausal gonadotropins. Only physicians experienced in infertility treatment should prescribe PREGNYL.

Anaphylaxis has been reported with urinary-derived hCG products.

The principal serious adverse reactions associated with PREGNYL are: (1) ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion, (2) rupture of ovarian cysts with resultant hemoperitoneum, (3) multiple births, and (4) arterial thromboembolism.

Other adverse reactions associated with PREGNYL use include, headache, irritability, restlessness, depression, fatigue, edema, and pain at the site of injection.

Hypersensitivity reactions, both localized and systemic in nature, have been reported.

Before prescribing PREGNYL, please read the Prescribing Information.

WOMN-1075029-0001 10/14

Please orient your device to the portrait position to return to the site.

more less
Selected Safety Information About PREGNYL® (chorionic gonadotropin for injection, USP)

PREGNYL is contraindicated in patients with prior allergic reaction to human chorionic gonadotropin (hCG).

PREGNYL should be used in conjunction with human menopausal gonadotropins. Only physicians experienced in infertility treatment should prescribe PREGNYL.

Anaphylaxis has been reported with urinary-derived hCG products.

The principal serious adverse reactions associated with PREGNYL are: (1) ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion, (2) rupture of ovarian cysts with resultant hemoperitoneum, (3) multiple births, and (4) arterial thromboembolism.

Other adverse reactions associated with PREGNYL use include, headache, irritability, restlessness, depression, fatigue, edema, and pain at the site of injection.

Hypersensitivity reactions, both localized and systemic in nature, have been reported.

Before prescribing PREGNYL, please read the Prescribing Information.